A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 272
- Population
- ALL · 50 Years
- Duration
- 2026-03-09 to 2029-08-22
- Intervention
- FWY003; Placebo
- Comparator
- Placebo
- Outcomes measured
- Change of geographic atrophy (GA) lesion area in the study eye — From Baseline to Month 18; Number of participants with adverse events (AEs) and serious adverse events (SAEs) — From first dose (Day 1) to Month 19; Change in visual function measure by ETDRS (Regular Luminance) Best Corrected Visual Acuity (BCVA) in the study eye — B…; Change in visual function measure by ETDRS Low Luminance Visual Acuity (LLVA) in the study eye — Baseline through Month…; Change in visual function measure by Quantitative contrast sensitivity function (qCSF) under regular luminance in the s…; Change in visual function measure by Low Contrast quantitative Visual Acuity (LCqVA) under regular luminance in the stu…; Change in visual function measure by LCqVA under low luminance in the study eye — Baseline through Month 18; Proportion of participants with ≥15 letters loss — Baseline through Month 18; Change in area of total and partial ellipsoid zone (EZ) attenuation in the macula in the study eye — Baseline through M…; Plasma concentrations of FWY003 — Baseline through Month 18; Rate of change of GA lesion area (square-root transformed) in the study eye — Baseline through Month 18; Change of GA lesion area (square-root transformed) — Baseline through Month 12
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Vision ageing · 100%Title contains controlled term: age-related macular degeneration. Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Title supplies longevity context: age-related. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 100%. These figures help sort records; they are not medical ratings.